Black Raspberry Confection in Preventing Oral Cancer in Healthy Volunteers
Märksõnad
Abstraktne
Kirjeldus
PRIMARY OBJECTIVES:
I. To select an optimal black raspberry confection based on altered gene expression and chemical profiles in healthy individuals exposed to 3 black raspberry-based amorphous functional confections with modulated bioactive release rate at two doses (4 g and 8 g).
OUTLINE: Participants are randomized to 1 of 6 arms after 2 weeks.
ARM I: Participants receive black raspberry (BRB) confection 1 fast release orally (PO) 4-6 hours apart thrice daily (TID) for 2 weeks.
ARM II: Participants receive BRB confection 2 fast release PO 4-6 hours apart TID for 2 weeks.
ARM III: Participants receive BRB confection 1 intermediate release PO 4-6 hours apart TID for 2 weeks.
ARM IV: Participants receive BRB confection 2 intermediate release PO 4-6 hours apart TID for 2 weeks.
ARM V: Participants receive BRB confection 1 prolonged release PO 4-6 hours apart TID for 2 weeks.
ARM VI: Participants receive BRB confection 2 prolonged release PO 4-6 hours apart TID for 2 weeks.
Kuupäevad
| Viimati kinnitatud: | 02/28/2019 |
| Esmalt esitatud: | 10/09/2013 |
| Hinnanguline registreerumine on esitatud: | 10/10/2013 |
| Esmalt postitatud: | 10/13/2013 |
| Viimane värskendus on esitatud: | 03/17/2019 |
| Viimati värskendus postitatud: | 03/18/2019 |
| Õppe tegelik alguskuupäev: | 06/30/2013 |
| Eeldatav esmane lõpetamise kuupäev: | 03/31/2020 |
| Eeldatav uuringu lõpetamise kuupäev: | 03/31/2020 |
Seisund või haigus
Sekkumine / ravi
Other: Fast release BRB confection
Other: Intermed release BRB confection
Other: Prolong release BRB confection
Faas
Käerühmad
| Arm | Sekkumine / ravi |
|---|---|
| Experimental: Arm I (Fast release BRB confection 4g) Participants receive one fast release BRB confection (4g) PO 4-6 hours apart thrice daily (TID) for 2 weeks. | |
| Experimental: Arm II (Fast release BRB confection 8g) Participants receive two fast release BRB confection (8g) PO 4-6 hours apart TID for 2 weeks. | |
| Experimental: Arm III (Intermed release BRBconfection 4g) Participants receive one intermediate release BRB confection (4g) PO 4-6 hours apart TID for 2 weeks. | |
| Experimental: Arm IV (Intermed release BRBconfection 8g) Participants receive two intermediate release BRB confection (8g) PO 4-6 hours apart TID for 2 weeks. | |
| Experimental: Arm V (Prolong release BRB confection 4g) Participants receive one prolonged release BRB confection (4g) PO 4-6 hours apart TID for 2 weeks. | |
| Experimental: Arm VI (Prolong release BRB confection 8g) Participants receive two prolonged release BRB confection (8g) PO 4-6 hours apart TID for 2 weeks. |
Abikõlblikkuse kriteeriumid
| Õppimiseks sobivad vanused | 18 Years To 18 Years |
| Uuringuks kõlblikud sood | All |
| Võtab vastu tervislikke vabatahtlikke | Jah |
| Kriteeriumid | Inclusion Criteria: - Be healthy, free-living adults - Be a non-smoker (defined as adults who have never smoked or who have not had a cigarette in the past ten years) - Agree to consume a standardized vitamin/mineral supplement and avoid other nutrition and alternative supplements for the duration of the study - Agree to follow a berry-restricted diet and to document any accidental consumption of restricted foods each day of the study - Agree to abstain from mouthwashes Exclusion Criteria: - Have an active metabolic or digestive illness including malabsorptive disorders, renal insufficiency, hepatic insufficiency, cachexia, or short bowel syndrome - Have an active or a recent history of any condition that causes altered immunity such as chronic inflammatory disease, autoimmune disorders, cancer, anemia, and blood dyscrasias - Have a known allergy or food intolerance to ingredients in study products (black raspberries),other berries, wheat, or soy - Are strict vegans (no consumption of animal, fish or egg products) - Are planning to conceive, or are currently pregnant or lactating - Are heavy alcohol consumers (defined as an average consumption of greater than 2 drinks/day) - Have a history of oral cancer or currently undergoing treatment of oral cancer - In the last month have had any active oral lesions or maladies or currently have any oral disease or obvious open sores in the oral cavity or surrounding the oral opening - Have strong gag reflex or problems swallowing that prohibit buccal brushing of the oral cavity - Have been on an antibiotic regime lasting for one week in the last 6 months |
Tulemus
Esmased tulemusnäitajad
1. Acceptance of candidate formulations, assessed using a 9 point hedonic scale (1 =dislike very much, 9 = like very much) [Up to day 14]
2. Bioavailability index, defined as the average rank of BRB effect in anthocyanins, ellagic acid, urolithins, and quercetin derivatives [Up to day 14]
3. Gene expression index, defined as the average rank of BRB effect on expression of genes responsive to BRBs and important to smoking and inflammatory response [Up to day 14]
